Modelling Tityus scorpion venom and antivenom pharmacokinetics. Evidence of active immunoglobulin G's F(ab')2 extrusion mechanism from blood to tissues
- PMID: 15500849
- DOI: 10.1016/j.toxicon.2004.07.032
Modelling Tityus scorpion venom and antivenom pharmacokinetics. Evidence of active immunoglobulin G's F(ab')2 extrusion mechanism from blood to tissues
Abstract
Modelling Tityus scorpion venom and antivenom pharmacokinetics. Evidence of active immunoglobulin G's F(ab')(2) extrusion mechanism from blood to tissues. We measured pharmacokinetic parameters for T. discrepans venom in rams. Forty, 75 or 100 microg/kg venom were injected subcutaneously in the inner side of the thigh. Plasma venom content (venenemia) was determined by enzyme-linked immunosorbent assay (ELISA) from 0 to 300 min after injecting venom. Venenemia was fit to a three-compartment model (inoculation site, plasma and extra vascular extracellular space), it was assumed that the venom may also be irreversibly removed from plasma. Calculated time course of venom content shows that at any time no more that 30% of the venom is present in plasma. Venenemia peaks at 1h and decays afterwards. Fluorescently labelled antivenom [horse anti-TityusF(ab')(2) or fraction antigen binding, immuglobulin without Fc chain covalently bound to fluorescine or fluorescamine] pharmacokinetics was determined. Although F(ab')(2) molecular weight is >/=10 times bigger that toxin's, the rate of outflow of F(ab')(2) from blood to tissues was approximately 4 times faster than the venom's outflow. Venom content in the injection site decays exponentially for >6h, this prediction was confirmed immunohistochemically. Only approximately 5% of the venom is eliminated in 10h; approximately 80% of the venom is in the tissues after 2h and remains there for >10h.
Similar articles
-
Initial volume of a drug before it reaches the volume of distribution: pharmacokinetics of F(ab')2 antivenoms and other drugs.Toxicon. 2007 Oct;50(5):653-65. doi: 10.1016/j.toxicon.2007.05.011. Epub 2007 Jun 12. Toxicon. 2007. PMID: 17689580
-
Pharmacokinetics of a F(ab')2 scorpion antivenom administered intramuscularly in healthy human volunteers.Int Immunopharmacol. 2010 Nov;10(11):1318-24. doi: 10.1016/j.intimp.2010.08.018. Epub 2010 Sep 17. Int Immunopharmacol. 2010. PMID: 20849955 Clinical Trial.
-
Toxicokinetic and toxicodynamic analyses of Androctonus australis hector venom in rats: optimization of antivenom therapy.Toxicol Appl Pharmacol. 2007 Feb 1;218(3):205-14. doi: 10.1016/j.taap.2006.11.003. Epub 2006 Nov 11. Toxicol Appl Pharmacol. 2007. PMID: 17198719
-
Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 1. Pharmacokinetics and pharmacodynamics of immunoglobulin antivenoms and related antibodies.Ann Emerg Med. 2001 Feb;37(2):189-95. doi: 10.1067/mem.2001.113135. Ann Emerg Med. 2001. PMID: 11174238 Review.
-
Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation.Clin Pharmacokinet. 2003;42(8):721-41. doi: 10.2165/00003088-200342080-00002. Clin Pharmacokinet. 2003. PMID: 12846594 Review.
Cited by
-
Pharmacokinetics and Biodistribution of Rhopalurus junceus Scorpion Venom in Tumor-Bearing Mice after Intravenous and Oral Administration.Iran Biomed J. 2019 Jul;23(4):287-96. doi: 10.29252/.23.4.287. Epub 2019 Apr 7. Iran Biomed J. 2019. PMID: 30954030 Free PMC article.
-
Scorpion Envenoming as an Emerging Public Health Problem in Paraguay, Bolivia, and Midwest Brazil: Involvement of Tityus confluens and the Need for a Panregional Evaluation of Available Antivenoms.Am J Trop Med Hyg. 2024 Oct 8;111(6):1166-1172. doi: 10.4269/ajtmh.24-0424. Print 2024 Dec 4. Am J Trop Med Hyg. 2024. PMID: 39378866
-
Emerging options for the management of scorpion stings.Drug Des Devel Ther. 2012;6:165-73. doi: 10.2147/DDDT.S24754. Epub 2012 Jul 5. Drug Des Devel Ther. 2012. PMID: 22826633 Free PMC article. Review.
-
Ischemic Stroke in a Child after a Probable Scorpion Sting.Am J Trop Med Hyg. 2021 Nov 29;106(3):959-961. doi: 10.4269/ajtmh.21-0880. Am J Trop Med Hyg. 2021. PMID: 34844215 Free PMC article.
-
Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens.Vaccine. 2016 Feb 24;34(9):1152-61. doi: 10.1016/j.vaccine.2016.01.016. Epub 2016 Jan 20. Vaccine. 2016. PMID: 26802604 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources